Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 6Unknown 3Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Breast Neoplasms 15Ovarian Neoplasms 9Recurrence 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Unrecognized Condition 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasm Epithelial 1Muscle Invasive Bladder Cancer 1Mesothelioma, Malignant 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Plasma Cell 1Hodgkin Disease 1HER2-positive Breast Cancer 1Genetic Predisposition to Disease 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Advanced Solid Tumors 1Advanced Breast Cancer 1

Interventions

Rituximab 57Cyclophosphamide 40Vincristine 26Prednisone 25Doxorubicin 22Cytarabine 18Lenalidomide 17Etoposide 17Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8zanubrutinib 7Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7R-CHOP protocol 6fludarabine phosphate 5Vindesine 5Radiotherapy 5Dexamethasone 5Decitabine 5Busulfan 5ibrutinib 4Methylprednisolone 4Epirubicin 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × liposomal doxorubicin × Clear all
NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02428751 2015-11-18

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Sun Yat-sen University

Phase 3 Unknown
216 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00333008 2006-09-26

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

The Alvin and Lois Lapidus Cancer Institute

Phase 2 Unknown
27 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡